5% Diclofenac Sodium Injection for animal use

Composition

Each ml contains Diclofenac Sodium 50mg

Properties:

Diclofenac sodium, sodium 2-[( 2,6-dichlorophenyl) amino] phenylacetate is one of the non-steroidal anti-inflammatory drugs (NSAIDs), belongs to the phenyl acetic acid derivatives. Diclofenac sodium as anti-inflammatory, analgesic and antipyretic effects is due to the decrease of the prostaglandin synthesis from arachidonic acid by inhibition of the cyclo-oxygenase. Its effect is 2~2.5 times stronger than indomethacin and 26~50 times stronger than acetylsalicylic acid. It is characterized by strong drug efficacy, mild adverse reactions, small doses, and small individual differences.

The binding rate of the drug to plasma protein is 99.7%. The half-life is 1 to 2 hours. According to the recommended dose and interval, there is no accumulation. The drug is metabolized by the liver, and about 60% of the therapeutic amount of metabolites is excreted from the kidneys, and the excretion of the original drug is less than 1%. The rest of the dose is in the form of metabolites, excreted into the intestines via bile, and cleared from the feces.

Indications

Antipyretic analgesics. Diclofenac sodium injection as anti-inflammatory and analgesic, is indicated for the control of pain and inflammation associated with musclo-skeletal disorders such as; arthritis, osteoarthritis, osteochondritis, bursitis, tendenitis and myositis, acute pneumonia, acute mastitis and enteritis. 

It is also used for the control of fever associated with infections or tissue degeneration in different animal species.

Dosage and Administration

Intramuscular injection:  

one dose, 1.25mg per 1kg body weight;

animals continuous used 1-3 days.

Precautions: It should be injected slowly.

Storage: Store in a cool, dry and dark place. Keep out of the reach of children.

Hebei Veyong pharmaceutical Co., Ltd, was established in 2002, located in Shijiazhuang City, Hebei Province, China, next to the Capital Beijing. She is a large GMP-certified veterinary drug enterprise, with R&D, production and sales of veterinary APIs, preparations, premixed feeds and feed additives. As Provincial Technical Center, Veyong has established an innovated R&D system for new veterinary drug, and is the nationally known technological innovation based veterinary enterprise, there are 65 technical professionals. Veyong has two production bases: Shijiazhuang and Ordos, of which the Shijiazhuang base covers an area of 78,706 m2, with 13 API products including Ivermectin, Eprinomectin, Tiamulin Fumarate, Oxytetracycline hydrochloride ects, and 11 preparation production lines including injection, oral solution, powder, premix, bolus, pesticides and disinfectant, ects. Veyong provides APIs, more than 100 own- label preparations, and OEM & ODM service.

Veyong attaches great importance to the management of EHS(Environment, Health& Safety) system, and obtained the ISO14001 and OHSAS18001 certificates. Veyong has been listed in the strategic emerging industrial enterprises in Hebei Province and can ensure the continuous supply of products.

Veyong established the complete quality management system, obtained the ISO9001 certificate, China GMP certificate, Australia APVMA GMP certificate, Ethiopia GMP certificate, Ivermectin CEP certificate, and passed US FDA inspection. Veyong has professional team of registeration, sales and technical service, our company has gained reliance and support from numerous customers by excellent product quality, high-quality pre-sales and after-sales service, serious and scientific management. Veyong has made long term cooperation with many internationally known animal pharmaceutical enterprises with products exported to the Europe, South America, Middle East, Africa, Asia, etc. more than 60 countries and regions.